aaiPharma Inc. (Nasdaq:AAII) said it has acquired a unique combination drugs including the pain-killer Darvocet from Athlon Pharmaceuticals.
“Upon approval, this product will provide an important alternative to
Darvocet-N(R) 100 for patients suffering from mild-to-moderate pain,”
commented Dr. Philip S. Tabbiner, President and CEO of aaiPharma.
Tabbiner said the agreement with Athlon “allows us to bring this product to market 12 months earlier than expected.
The total market for propoxyphene (Darvocet) is worth more than $500 million, according to Verispan data. The new line extension combines propoxyphene with napsylate/acetaminophen in unique dose form.
This new line extension is expected to add substantial value to aaiPharma’s growing portfolio of branded pain management products, the company said.
Separate from this acquisition, aaiPharma plans to launch another Darvon line extension later this year, in addition to the launch of Darvon Compound 32, which was announced in June 2003.